Evidence mapPaperPMID 39519213Full record

ReviewInternational journal of molecular sciences2024

CK and LRRK2 Involvement in Neurodegenerative Diseases.

Valentina Bova, Deborah Mannino, Anna Paola Capra, Marika Lanza, Nicoletta Palermo, Alessia Filippone, Emanuela Esposito

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valentina BovaDepartment of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.ORCID 0000-0002-6927-8997
Deborah ManninoDepartment of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.
Anna Paola CapraDepartment of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.ORCID 0000-0002-1428-3609
Marika LanzaDepartment of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.
Nicoletta PalermoDepartment of Biochemical, Dental, Morphological and Functional Imaging, University of Messina, Via Consolare Valeria, 98125 Messina, Italy.
Alessia FilipponeDepartment of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.ORCID 0000-0002-9642-6844
Emanuela EspositoDepartment of Chemical, Biological, Pharmaceuticals and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres, 98166 Messina, Italy.ORCID 0000-0002-2663-6387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases (NDDs) are currently the most widespread neuronal pathologies in the world. Among these, the most widespread are Alzheimer's disease (AD), dementia, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)-all characterized by a progressive loss of neurons in specific regions of the brain leading to varied clinical symptoms. At the basis of neurodegenerative diseases, an emerging role is played by genetic mutations in the leucine-rich repeat kinase 2 (LRRK2) gene that cause increased LRRK2 activity with consequent alteration of neuronal autophagy pathways. LRRK2 kinase activity requires GTPase activity which functions independently of kinase activity and is required for neurotoxicity and to potentiate neuronal death. Important in the neurodegeneration process is the upregulation of casein kinase (CK), which causes the alteration of the AMPK pathway by enhancing the phosphorylation of α-synuclein and huntingtin proteins, known to be involved in PD and HD, and increasing the accumulation of the amyloid-β protein (Aβ) for AD. Recent research has identified CK of the kinases upstream of LRRK2 as a regulator of the stability of the LRRK2 protein. Based on this evidence, this review aims to understand the direct involvement of individual kinases in NDDs and how their crosstalk may impact the pathogenesis and early onset of neurodegenerative diseases.

Indexed as

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Neurodegenerative DiseasesAnimalsAutophagyHumansMutationPhosphorylationLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humancasein kinasesdegradative pathwaysleucine riche-repeat kinaseneurodegeneration

Identifiers

PMID39519213
PMCPMC11546471

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.